Federal Register / Vol. 72, No. 168 / Thursday, August 30, 2007 / Notices 50111 

Coast Financial Holding Inc. In certain 

circumstances. 

Board of Governors of the Federal Reserve 

System, August 24, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E7–17142 Filed 8–29–07; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR Part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The application also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than September 25, 

2007. 

A. Federal Reserve Bank of 

Philadelphia (Michael E. Collins, Senior 

Vice President) 100 North 6th Street, 

Philadelphia, Pennsylvania 19105–

1521: 

1. Harleysville National Corporation, 

Harleysville, Pennsylvania; to retain 

19.9 percent of the voting shares of 

Berkshire Bancorp, Inc., and thereby 

indirectly retain voting shares of 

Berkshire Bank, both of Wyomissing, 

Pennsylvania. 

B. Federal Reserve Bank of Cleveland 

(Douglas A. Banks, Vice President) 1455 

East Sixth Street, Cleveland, Ohio 

44101–2566: 

1. PNC Financial Services Group, Inc., 

Pittsburgh, Pennsylvania; to merge with 

Yardville National Bancorp, Hamilton, 

New Jersey, and thereby indirectly 

acquire 100 percent of Yardville 

National Bank, Yardville, New Jersey, 

and 19.9 percent of the voting shares of 

Bucks County Bank, Doylestown, 

Pennsylvania. 

Board of Governors of the Federal Reserve 

System, August 27, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E7–17191 Filed 8–29–07; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies; 

Correction 

This notice corrects a notice (FR Doc. 

E7-16882) published on page 49009 of 

the issue for Monday, August 27, 2007. 

Under the Federal Reserve Bank of 

Richmond heading, the entry for 

Virginia Community Capital, Inc., 

Christiansburg, Virginia, is revised to 

read as follows: 

A. Federal Reserve Bank of 

Richmond (A. Linwood Gill, III, Vice 

President) 701 East Byrd Street, 

Richmond, Virginia 23261-4528: 

1. Virginia Community Capital, Inc., 

which is currently operating as a 

Community Development Financial 

Institution; to become a bank holding 

company by acquiring 100 percent of 

the voting shares of Community Capital 

Bank of Virginia, both of Christiansburg, 

Virginia. 

In connection with this application, 

Applicant also has applied to continue 

to engage in lending and community 

development activities, pursuant to 

sections 225.28(b)(1), (b)(12)(i), and 

(b)(12)(ii) of Regulation Y. 

Comments on this application must 

be received by September 21, 2007. 

Board of Governors of the Federal Reserve 

System, August 27, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E7–17192 Filed 8–29–07; 8:45 am] 

BILLING CODE 6210–01–S 

GENERAL SERVICES 

ADMINISTRATION 

Office of Small Business Utilization; 

Small Business Advisory Committee 

Renewal of the Small Business 

Advisory Committee 

AGENCY: Office of Small Business 

Utilization, GSA. 

ACTION: Notice. 

SUMMARY: Under the provisions of the 

Federal Advisory Committee Act of 

1972, (5 U.S.C. Appendix, as amended), 

the Sunshine in the Government Act of 

1976 (5 U.S.C. 552b, as amended), and 

41 CFR 102–3.65, the U.S. General 

Services Administration gives notice 

that it intends to renew the Small 

Business Advisory Committee (SBAC), 

as a discretionary Federal advisory 

committee. 

The Office of Small Business 

Utilization (OSBU) has responsibility 

for overseeing the General Services 

Administration’s (GSA) best efforts to 

achieve the small business procurement 

goals set by the Small Business 

Administration (SBA). Several 

procurement preference program goals 

(HUBZone, Service-Disabled Veteran, 

Women-Owned) have proven to be 

difficult for GSA and the Federal 

government as a whole to reach. Other 

procurement issues such as 

subcontracting, size standards, and 

availability of small manufacturers, 

impact the government beyond 

procurement goals. 

As the Federal government’s primary 

contracting agency, GSA’s procurement 

practices and policies to a large extent 

affect all other Federal agencies. The 

GSA Small Business Advisory 

Committee (SBAC) was established by 

the OSBU to solicit the ideas and 

experience of association executives and 

small business owners in the hopes that 

their recommendations would serve to 

make the GSA small business program 

more effective in the future, and in turn, 

the entire Federal government’s 

program. 

Committee members will represent a 

cross-section of various socio-economic 

groups and chambers of commerce. One 

member will be appointed from a 

chamber of commerce from each of the 

following socio-economic groups: 

African American, Asian American / 

Pacific Islander, Hispanic, Native 

American / Alaska Native, Veteran / 

Service-Disabled Veteran, and Womenowned businesses. Additional members 

may be selected based on their expertise 

in government contracting, doing 

business with the Federal government, 


rfrederick on PROD1PC67 with NOTICES
50112 Federal Register / Vol. 72, No. 168 / Thursday, August 30, 2007 / Notices 

and small business knowledge in 

general. 

FOR FURTHER INFORMATION CONTACT: 

Aaron Collmann, Room 6029, GSA 

Building, 1800 F Street, NW., 

Washington, DC 20405 (202) 501–1021 

or email at sbac@gsa.gov. 

SUPPLEMENTARY INFORMATION: This 

notice is published in accordance with 

the provisions of the Federal Advisory 

Committee Act (FACA) (Pub. L. 92–

463). 

Dated: August 27, 2007 

Michael J. Rigas 

Deputy Associate Administrator,Office of 

Small Business Utilization,General Services 

Administration. 

[FR Doc. 07–4282 Filed 8–28–07; 12:35 pm] 

BILLING CODE 6820–34–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2007N–0041] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Administrative Procedures for the 

Clinical Laboratory Improvement 

Amendments of 1998 Categorization; 

Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice that appeared in the Federal 

Register of May 16, 2007 (72 FR 27573). 

The document announced that a 

proposed collection of information had 

been submitted to the Office of 

Management and Budget (OMB) for 

review and clearance under the 

Paperwork Reduction Act of 1995. The 

document was published with an error. 

This document corrects that error. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, Jr., Office of the Chief 

Information Officer (HFA–250), Food 

and Drug Administration, 5600 Fishers 

Lane, Rockville, MD 20857, 301–827–

1472. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

E7–9435, appearing on page 27573 in 

the Federal Register of Wednesday, May 

16, 2007, the following correction is 

made: 

1. On page 27574, in the third 

column, in the third full paragraph, the 

sentence ‘‘The likely respondents for 

this collection are Investigational New 

Drug Application Sponsors.’’ is 

corrected to read ‘‘The likely 

respondents for this collection of 

information are manufacturers of 

medical devices.’’

Dated: August 23, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–17153 Filed 8–29–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Office of the Commissioner; Statement 

of Organizations, Functions, and 

Delegations of Authority 

Part D, Chapter D–B, (Food and Drug 

Administration), of the Statement of 

Organization, Functions, and 

Delegations of Authority for the 

Department of Health and Human 

Services (35 FR 3685, February 25, 

1970, and 60 FR 56605, November 9, 

1995, 64 FR 36361, July 6, 1999, and in 

pertinent part at 57 FR 54239) is being 

amended to reflect the restructuring of 

the Office of the Commissioner (OC), 

Food and Drug Administration (FDA). 

This reorganization includes the 

establishment of four Deputy-level 

offices within the Office of the 

Commissioner, the changes are as 

follows: 

I. Under Part D, Food and Drug 

Administration, delete the Office of the 

Commissioner (DA) in its entirety and 

replace with the following: 

DA.10 Organization. The Food and 

Drug Administration (FDA) is headed by 

the Commissioner, Food and Drug and 

includes the following organizational 

units: 

Office of the Commissioner (DA), 

Office of the Chief Counsel (DAA), 

Office of the Chief of Staff (DAB), Office 

of International and Special Programs 

(DAL), Office of Operations (DAM), 

Office of Policy, Planning and 

Preparedness (DAH), Office of Scientific 

and Medical Programs (DAE). 

DA.20 Functions 

A. Office of the Commissioner D(A)—

The Office of the Commissioner (OC) 

includes the Commissioner and Deputy 

Commissioner who are responsible for 

the efficient and effective 

implementation of FDA mission. 

B. Office of the Chief Counsel 

(DAA)—The Office of the Chief Counsel 

(OCC) is also known as the Food and 

Drug Division, Office of the General 

Counsel, Department of Health and 

Human Services), while 

administratively within the Office of the 

Commissioner, is part of the Office of 

the General Counsel of the Department 

of Health and Human Services. 

1. Is subject to the professional 

supervision and control of the General 

Counsel, Department of Health and 

Human Services (HHS), and represents 

FDA in court proceedings and 

administrative hearings with respect to 

programs administered by FDA. 

2. Provides legal advice and policy 

guidance for programs administered by 

FDA. 

3. Acts as liaison to the Department of 

Justice and other Federal agencies for 

programs administered by FDA. 

4. Drafts or reviews all proposed and 

final regulations and Federal Register 

notices prepared by FDA. 

5. Performs legal research and gives 

legal opinions on regulatory issues, 

actions, and petitions submitted to FDA. 

6. Reviews proposed legislation 

affecting FDA that originates in HHS or 

on which Congress requests the views of 

the Department. 

7. Provides legal advice and 

assistance to the Office of the Secretary 

on matters within the expertise of the 

Chief Counsel. 

C. Office of the Chief of Staff (DAB)—

The Office of the Chief of Staff (OCOS): 

1. Advises and provides integrated 

policy analysis and strategic 

consultation to the Commissioner, 

Deputy Commissioners, Associate 

Commissioners, Center Directors and 

other FDA officials on activities and 

issues that affect significant agency 

programs, projects and initiatives. Often 

this function involves the most difficult 

problems, crisis situations and 

extremely complex issues of FDA. 

2. Provides leadership, coordination 

and management of the Commissioner’s 

priority policies and issues across the 

Office of the Commissioner and FDAwide. Identifies, triages, supervises and 

tracks related actions from start to finish 

in conjunction with senior leadership 

across FDA. 

3. Provides ddidrect support to the 

Commissioner of Food and Drugs and 

serves as major point of contact between 

the FDA Centers and Offices and the 

Commissioner. 

4. Serves as the principal liaison to 

HHS and coordinates and manages 

activities between FDA and HHS. Works 

with the FDA Centers and Offices to 

ensure assignments or commitments 

made related to these activities are 

carried out. 

5. Serves as one of the 

Commissioner’s primary strategic 

liaisons with staff, partners, and the 

community at large. 

6. Manages budget and resources and 

provides operation oversight for the 

FDA’s Office of Legislation, Office of the 


rfrederick on PROD1PC67 with NOTICES